Organic Active Ingredients TRIZ Cases

Sepiapterin crosses the blood-brain barrier to deliver tetrahydrobiopterin precursors directly into neurons.

2-Phenyl-3H-imidazo[4,5-b]pyridine derivatives inhibit mammalian ROR1 tyrosine kinase activity.

Novel imidazopyrrolidinone compounds bind to MDM2 and MDM4 proteins.

A multipart fluid system incorporates phosphate into anticoagulation and treatment fluids to maintain stable chemical concentrations during dialysis therapy.

Reducing IEX-1 polypeptide expression inhibits venous neointimal hyperplasia, extending hemodialysis vascular access patency.

N-(5-phenylpyrazol-3-yl)-1H-indol-5-amine compounds inhibit Traf2- and Nck-interacting kinase activity.

Encapsulating polyunsaturated fatty acids in liposomes prevents oxidation, maintaining skin-whitening efficacy while avoiding discoloration.

Inhalation of volatile HDAC inhibitors bypasses the blood-brain barrier, enabling direct treatment of neurological disorders and cancers.

Phosphorus-substituted triazolo compounds overcome acquired resistance to existing c-MET inhibitors.

C-3 cycloalkenyl triterpenoids prevent HIV capsid assembly, addressing incomplete viral suppression caused by drug-resistant variants.

Polyethylene glycol moieties modify kappa opioid agonist structures to target peripheral nervous systems.

Jak1 and Jak2 inhibitors induce hair growth by modulating cytokine signaling pathways in subjects with alopecia areata.

Allogeneic T cells target Epstein-Barr virus antigens via HLA restriction to eliminate lymphoproliferative disorder cells.

A distillation column separates alkyl alcohol from alkylene oxide using an intermediary water stream to form a low-boiling azeotrope.

Antisense oligonucleotides inhibit pro-atherogenic microRNAs to restore TIMP3 and RECK, avoiding surgical risks.

Antisense oligonucleotides lower dynamin 2 expression to treat centronuclear myopathies and neuropathies.

Polyamine-lipid co-polymers form micellar carriers that protect siRNA from enzymatic degradation while enhancing cell membrane penetration.

High-amylose starch prevents moisture-induced degradation of thyroid hormones in soft capsules.

Covalent binding to mutated Btk residues resolves the trade-off between inhibition efficacy and off-target effects on other kinases.

Combining BACE1 inhibitors with mGluR agonists restores synaptic plasticity in neural tissue.

HDAC inhibitors modulate histone acetylation to restore frataxin gene function, addressing the root cause of Friedreich's ataxia.

A closed-system bladder catheter assembly manages chemotherapy fluid flow through a pre-assembled stopcock and drain lumen.

A targeted nutritional supplement delivers essential vitamins and minerals to support maternal health.

Composite excipients in Levothyroxine sublingual tablets maintain physicochemical stability and dissolution profiles despite formulation complexity.

A bicyclic compound with specific halogen and alkyl substituents inhibits acetyl-CoA carboxylase to treat metabolic disorders.

Biodegradable polymeric nanoparticles replace viral vectors to deliver therapeutic genes into stem cells, avoiding insertional mutagenesis and immunogenicity.

Deuterated and fluorinated primary amines inhibit RPE65 while sequestering toxic retinal metabolites to prevent photoreceptor damage.

Merging targeting moieties into single repressors modulates pluralities of associated genes while reducing off-target effects.

Moist heat sterilization of oxidation-susceptible API in sealed flexible bags prevents impurity formation without nitrogen blankets.

Capsid assembly modulators induce aberrant particle formation to suppress replication and overcome drug resistance.

Administering natriuretic peptides and neprilysin inhibitors addresses limited early-stage effectiveness by mitigating cytokine storms and organ damage.

Lock nucleic acids inhibit guide RNA activity until a trigger displaces them, resolving temporal control issues in CRISPR-Cas genome editing.

A crystalline hydrochloride salt form of a kappa opioid receptor antagonist improves stability and bioavailability for clinical development.

Amino acid substitutions at positions 286 and 298 extend plasma half-life, enabling on-demand hemostatic treatment for inhibitor-positive patients.

Wet spun microfibers with hydrophobic inner cores and hydrophilic outer layers prevent burst release of trapped drugs to ensure sustained delivery.

A viral vector delivers Fas-chimera to endothelial cells within malignant gliomas.

Modified antisense oligomers target myostatin pre-mRNA splice sites, reducing protein levels without the genotoxicity risks of direct gene manipulation.

A water-permeable pouch uses variable packing density to modulate release of water-soluble components.

Lipid nanoparticles deliver insulin peptides and anti-inflammatory agents to pancreatic lymph nodes via intestinal barrier penetration.

Intravenous cangrelor delivers rapid platelet inhibition during percutaneous coronary intervention procedures.

INCB3284 CCR2 inhibitor reduces fluid requirements and delays hemodynamic decompensation in hemorrhagic shock.

Mavoglurant antagonizes mGluR5 receptors to treat opioid use disorder, preventing relapse while alleviating associated depressive symptoms.

Protease-cleavable nanocapsules deliver proteins into cells while maintaining biological activity and avoiding structural denaturation.

Replacing CREMOPHOR EL with a composite excipient system eliminates infusion-related side effects while maintaining drug efficacy.

Substituted pyrrolidin-3-one oxime compounds enhance endometrial receptivity to improve embryo implantation success rates despite low IVF outcomes.

FAO pathway inhibitors disrupt pancreatic cancer energy metabolism to overcome chemoresistance.